卡维地洛与比索洛尔对慢性阻塞性肺疾病合并心力衰竭患者心肺功能及生活质量的影响

doi:10.3969/j.issn.1671-7171.2019.01.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】 探讨卡维地洛与比索洛尔治疗慢性阻塞性肺疾病(COPD)合并心力衰竭(HF)患者的临床疗效及其对心肺功能、生活质量的影响。【方法】 回顾性分析2017年2月至2018年1月本院收治的138例COPD合并HF患者的临床资料,根据治疗药物的不同将其分为对照组与观察组,每组各69例。两组均给予常规内科治疗,对照组应用卡维地洛,观察组应用比索洛尔,疗程为6个月。比较两组临床疗效及其心、肺功能,应用圣乔治呼吸问卷(SGRQ)评分评价其生活质量。【结果】 观察组总有效率为92.8%(64/69)显著高于对照组的81.2%(56/69),差异具有统计学意义(χ²=4.089,P=0.043＜0.05)。治疗6个月后,对照组肺活量(VC)与治疗前比较,差异无统计学意义(P>0.05);观察组VC较治疗前明显升高(P<0.05)。两组治疗后静息心率、6 min步行距离、峰值呼吸流速(PEF)均较治疗前明显改善,且观察组明显优于对照组,差异均有统计学意义(P<0.05)。两组治疗后活动能力、呼吸症状、疾病影响评分及SGRQ总评分均显著低于治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。对照组不良反应发生率为2.90%(2/69)低于观察组的4.35%(3/69),两组比较差异无统计学意义(χ²=0.208,P=0.65＜0.05)。【结论】 卡维地洛与比索洛尔均可显著改善COPD合并HF患者的心、肺功能,并能提升其生活质量,且安全性高,但比索洛尔疗效优于卡维地洛。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张浩
	王赫
	顾磊

关键词 ：肺疾病, 慢性阻塞性, 心力衰竭, 卡唑类/治疗应用, 比索洛尔/治疗应用

Abstract：【Objective】 To investigate the clinical efficacy of carvedilol and Bisoprolol in the treatment of patients with chronic obstructive pulmonary disease (COPD) complicated with heart failure (HF) and their effects on cardiopulmonary function and quality of life. 【Methods】 The clinical data of 138 patients with COPD combined with HF from February 2017 to January 2018 were analyzed retrospectively. According to the difference of treatment drugs, they were divided into control group and observation group with 69 cases in each group. Both groups were given routine medical treatment, the control group was treated with carvedilol and the observation group with Bisoprolol for 6 months. The clinical efficacy and heart and lung function of the two groups were compared. The quality of life (QOL) was evaluated by score of St. George's Respiratory questionnaire (SGRQ). 【Results】 The total effective rate was 92.8% (64/69) in the observation group and 81.2% (56/69) in the control group. The difference was statistically significant (χ²=4.089,P=0.043＜0.05). After 6 months of treatment, the vital capacity of (VC) in the control group was not significantly different from that before treatment (P>0.05), and the VC in the observation group was significantly higher than that before treatment (P<0.05). The resting heart rate, walking distance of 6 min and peak respiratory velocity (PEF) were significantly improved in the two groups after treatment, and the difference was statistically significant in the observation group than in the control group (P<0.05). After treatment, the activity ability, respiratory symptoms, disease impact score and total SGRQ score of the two groups were significantly lower than those of the control group (P<0.05), and those of the observation group were lower than those of the control group (P<0.05). The incidence of adverse reactions in the control group was 2.90% (2/69), which was lower than that in the observation group (4.35%). There was no significant difference between the two groups (χ²= 0.208,P<0.05). 【Conclusion】 Both carvedilol and bisoprolol could significantly improve the heart and lung function of COPD patients with HF, and improve their quality of life, but the efficacy of bisoprolol is better than that of carvedilol.

Key words： Pulmonary Disease Chronic Obstructive Heart Failure Carbazoles/TU Bisoprolol/TU

收稿日期: 2018-11-06

PACS:

R563

引用本文:

张浩, 王赫, 顾磊. 卡维地洛与比索洛尔对慢性阻塞性肺疾病合并心力衰竭患者心肺功能及生活质量的影响[J]. 医学临床研究, 2019, 36(1): 62-64.
ZHANG Hao, WANG He, GU Lei. Effects of Carvedilol and Bisoprolol on Cardiopulmonary Function and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease Complicated with Heart Failure. JOURNAL OF CLINICAL RESEARCH, 2019, 36(1): 62-64.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2019.01.019 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2019/V36/I1/62

[1] Anthonisen NR, Skeans MA, Wise RA,et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial[J].Ann Int Med,2005,142(4):233-239.
[2] 武国霞.比索洛尔联合培哚普利治疗慢性充血性心力衰竭临床观察[J].河北医药,2013,35(16):2466-2467.
[3] 周慧霞, 加尔肯·拉斯拜, 白云峰,等. 慢性阻塞性肺疾病长期随访中肺功能的变化及影响因素[J].医学临床研究, 2017, 34(8):1640-1642.
[4] 曾惠权, 潘春予, 霍炽荣,等. 噻托溴铵粉吸入剂治疗慢性阻塞性肺疾病急性加重期患者的临床疗效[J].湖南师范大学学报(医学版), 2015,12(4):59-61.
[5] 田跃雷,王跃慧,魏淑莲,等.比索洛尔与卡维地络治疗心力衰竭合并COPD对患者心功能和SGRQ评分的影响分析[J].河北医药,2015,37(24):3737-3740.
[6] Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients[J].Ann Epidemiol,2006,16(1):63-70.
[7] Londo o KL, Formiga F, Chivite D, et al. Prognostic influence of prior chronic obstructive pulmonary disease in patients admitted for their first episode of acute heart failure[J].Intern Emerg Med,2018,13(3): 351-357.
[8] Fisher K, Stefan MF, Darling D, et al. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the worcester heart failure study[J].Chest,2015,147(3):637-645.
[9] Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes[J].Int J Chron Obstruct Pulmon Dis,2014,9:1145-1154.
[10] DiNicolantonio JJ, Lavie CJ,Fares H, et al. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol) [J].Am J Cardiol,2013,111(5):765-769.